Table 1.
Age | Diagnosis | Karyotype | % Bone Marrow Blasts | R-IPSS Score and Category for Primary MDS Patients | Bortezomib Dose (mg/m2) | # cycles | Best Response, Time to Best Response (cycles) | Duration of Best Response, (months) | Prior treatment(s) (excluding GFs) | Prior hypomethylating agent | Proceeded to SCT |
---|---|---|---|---|---|---|---|---|---|---|---|
73 | t-MDS | −7 | 2 | 0.7 | 2 | SD, 1 | 4 | For MDS: azacitidine X 5, then lenalidomide For lung cancer: Chemotherapy and XRT | A | ||
67 | RAEB-2 | NL | 11 | 6.5, Very high | 0.7 | 7 | mCR, 3 | 6 | Y | ||
76 | RAEB-2 | NL | 16 | 5.5, High | 0.7 | 7 | CR, 3 | ||||
81 | RAEB-2 | complex | 10 | 8.5, Very high | 1 | 2 | NR | ||||
87 | RAEB-1 | −7 | 8 | 1 | 3 | NR | decitabine | D | |||
74 | t-MDS | del(20q), −7 | 8 | 1 | 2 | PCyR, 2 | 3 | prior treatment for APML | Y | ||
79 | RAEB-2 | del(5q) with additional complex | 11 | 1 | 2 | NR | lenalidomide X 5 years for del5q MDS | ||||
75 | MDS/MPN | NL | 4 | 2.5, Low | 1 | 2 | NR | hydroxyurea for HES | |||
73 | RAEB-2 | NL | 0* | removed | |||||||
67 | RAEB-2 | −Y | 10 | 3, Low | 1 | 1 | NR | Y | |||
78 | RCMD | del(5q), del(20q) | 2 | 3, Low | 1.3 | 9 | PCyR, 3 | 3 | |||
62 | t-CMML | t(11;19) | 2 | 1.3 | 3 | NR | |||||
63 | CMML-2 | NL | 14 | 5, High | 1.3 | 3 | NR | ||||
78 | AML | NL (FLT3 ITD+, NPM1 +) | 67 | 1.3 | 1 | NR | |||||
58 | AML | NL | 89 | 1.3 | 2 | NR | multiple chemotherapies for AML, SCT | D | |||
63 | AML | del(5q) with additional complex | 90 | 1.3 | 3 | NR | decitabine, RIC SCT | D | |||
79 | AML | del(12p) | 40 | 1.3 | 1 | NR | hydroxyurea for CMML | ||||
64 | RARS | complex | 2 | 1.3 | 9 | CCyR, 3 | 15 (persists) | azacitidine, lenalidomide, thalidomide | A | ||
72 | AML | i(11) | 40 | 1.3 | 6 | CR, 3 | 3 | ||||
72 | t-AML | −7 | 15 | 1.3 | 2 | NR | For AML: AML induction, azacitidine X 8 For LPL: fludarabine |
A | |||
54 | AML | NL | 38 | 1.3 | 1 | NR | AML induction, SCT, azacitidine | A | |||
54 | AML | t(3;3) | 60 | 1.3 | 2 | NR | multiple prior inductions | ||||
78 | AML | NL | 45 | 1.3 | 1 | NR | decitabine X 8 cycles | D |
= removed prior to start due to rapidly progressive disease, GFs = growth factors, t-MDS = therapy-related MDS, t-AML = therapy-related AML, mCR = marrow complete remission, PCyR = partial cytogenetic response, CCyR = complete cytogenetic response, NR = no response, CR = complete remission, HES = hypereosinophilic syndrome, APML = acute promyelocytic leukemia. A=azacitidine, D=decitabine.